Media Center
Press Releases

Press Releases

19 Jun 18
Increasing focus on high-value generics and development of innovative products will drive the growth of mid-size pharma companies, says GBI Research

The worldwide pharmaceutical market is facing challenges due to crippling pricing pressure of novel products and a reducing number of pipeline products due to high failure rates. Therefore, mid-size pharma companies are gaining importance in the market as these are mainly focusing on developing generic products, which helps to reduce overall healthcare cost burden at country level, according to business intelligence provider GBI Research.

Read post
21 May 18
Increasing focus on high-value generics and development of innovative products will drive the growth of mid-size pharma companies, says GBI Research

The worldwide pharmaceutical market is facing challenges due to pricing pressure and fewer pipeline products due to high failure rates. Therefore, mid-size pharma companies are gaining importance in the market, as they mainly focus on developing generic products, which help to reduce the overall healthcare cost burden at country level, according to business intelligence provider GBI Research.

Read post
09 May 18
Asia-Pacific breast cancer market to outstrip $4.75 billion by 2024, says GBI Research

The breast cancer market across the Asia-Pacific (APAC) region, which includes India, China, Australia, South Korea and Japan, is forecast to grow from $2.16 billion in 2017 to $4.75 billion by 2024, at a compound annual growth rate of 11.9%, according to business intelligence provider GBI Research.

Read post
08 May 18
Innovation in schizophrenia therapeutics holds promise of a better quality of life for sufferers, says GBI Research

Schizophrenia is a chronic mental disorder that affects 1% of the global population. Commercial dopamine-receptor blockade is effective in treating the positive symptoms (auditory and visual hallucinations), but there are no commercial drugs available for the treatment of negative (loss or decreased ability to speak) and cognitive symptoms, according to business intelligence provider GBI Research.

Read post
01 May 18
Asia-Pacific psoriasis therapeutics market to reach $1.9 billion by 2024, says GBI Research

The Asia-Pacific (APAC) psoriasis therapeutics market, which includes India, China, Australia, South Korea and Japan, is set to grow from $933.1m in 2017 to $1,997.3m in 2024, at a compound annual growth rate (CAGR) of 11.5%, according to business intelligence provider GBI Research.

Read post